Thursday 16 October, 2025
Introduction: Busulfan is a chemotherapeutic drug that is widely used for conditioning regimens before hematopoietic stem cell transplantation (HSCT) for…
Read morePoster: Drug/Disease Modelling - Oncology
Population Pharmacokinetic Analysis Supporting Fixed and Extended-Interval Dosing of Balstilimab Alone and Combined with Botensilimab in Advanced Solid Tumors
Thursday 16 October, 2025
Background: Optimizing dosing regimens for therapeutic antibodies through population pharmacokinetic modeling is critical for maximizing clinical benefit while maintaining practical…
Read morePopulation modeling to exploit Phase I dose-finding trials data in pediatric oncology exemplified by brigatinib (ITCC-098) and bosutinib (ITCC-054)
Thursday 16 October, 2025
Introduction Phase I trials aim to establish the recommended phase II dose (RP2D) by assessing drug safety [1]. In pediatric…
Read moreTranslational PK/PD-Efficacy modelling for camizestrant (SERD)
Thursday 16 October, 2025
Introduction/Objectives: The main objectives of this project are to establish a quantitative PK/PD-Efficacy relationship for the next generation oral selective…
Read moreAlternative Model-Based Dosing Strategies for Subcutaneous Nivolumab to Improve Cost-Effectiveness in NSCLC Patients
Thursday 16 October, 2025
Introduction: The increasing use of immune checkpoint inhibitors, such as nivolumab, places a significant financial burden on healthcare systems, contributes…
Read moreQuantifying the exposure-toxicity relationship of [177Lu]Lu-PSMA-I&T using a population PK-PD model
Thursday 16 October, 2025
Objectives: [¹77Lu]Lu-PSMA is an approved radioligand therapy that prolongs progression free survival and overall survival in patients with metastatic castration-resistant…
Read moreTranslating Preclinical Insights into Clinical Outcomes: A Predictive Framework for Overall response rate and time to progression in Solid Tumors
Thursday 16 October, 2025
Introduction: Assessment of tumor dynamics is crucial in cancer therapy evaluation. For solid tumors, RECIST [1] classify tumor dynamics into…
Read morePredicting VEGF Levels in Cancer Patients Using Machine and Deep Learning
Thursday 16 October, 2025
Introduction: Increased VEGF expression in the tumor microenvironment contributes to tumor progression and metastasis [1]. Bevacizumab, a recombinant humanized monoclonal…
Read moreCovariate Analysis of Metabolizing Enzymes and Efflux Transporters and Model based Therapeutic Drug Monitoring in Females Receiving Olaparib
Thursday 16 October, 2025
Objective Olaparib is an inhibitor of poly ADP ribose polymerase (PARPi) used in treatment of ovarian cancer with BRCA1/2 mutation,…
Read morePopulation time-activity modeling and simulation supporting the reduced dosimetry collection for radioligand therapy (RLT) clinical trials
Thursday 16 October, 2025
Objectives: Dosimetry is an essential measurement in radioligand therapy (RLT) as it enables dosage and regimen selection to deliver safe…
Read more